New Microplate Reader Optimized for Fluorescent and Bioluminescent Assays
By LabMedica International staff writers Posted on 13 Feb 2014 |
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Biotech and other life science researchers now have available a new microplate reader system that provides superior sensitivity, performance, and flexibility with minimal user intervention.
Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.
The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.
The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.
Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”
Related Links:
Promega Corporation
Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.
The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.
The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.
Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”
Related Links:
Promega Corporation
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples